Peter Vanderslice, PhD

Dr. Vanderslice has spent over 20 years leading teams focused on the development of small molecule compounds that bind and modulate the function of integrins and chemokine receptors. The majority of his professional career has been in the pharmaceutical industry, where he gained familiarity with each stage of the pipeline from discovery to progression into clinical trials. Dr. Vanderslice has led teams working on several pre-clinical programs involving efforts in drug screening, lead compound characterization, and the development of preclinical animal models.

See Publications

Texas Heart Institute Positions

Senior Investigator and Director, MCRL, Molecular Cardiology Research

Interests

Non-invasive diagnostic imaging technologies

Education

Undergraduate:

University of Maryland
Postgraduate:

University of Texas at Austin (PhD)
Fellowships:

University of California San Francisco

Honors, Awards and Memberships

Parker B. Francis Fellowship in Pulmonary Research, University of California, San Francisco, CA
The Texas Heart Institute Academic Professional Staff

Publications

Guan, Y.-S., Ershad, F., Rao, Z. et al. (2022). Elastic electronics based on micromesh-structured rubbery semiconductor films. Nat Electron. https://doi.org/10.1038/s41928-022-00874-z.

Mendiola, E. A., Neelakantan, S., Xiang, Q. et al. (2022). Contractile adaptation of the left ventricle post-myocardial infarction: predictions by rodent-specific computational modeling. Ann Biomed Eng. https://doi.org/10.1007/s10439-022-03102-z.

Hickman, A., Koetsier, J., Kurtanich, T. et al. (2022). LFA-1 activation enriches tumor-specific T cells in a cold tumor model and synergizes with CTLA-4 blockade. J Clin Invest 132, e154152. https://doi.org/10.1172/JCI154152.

Babaei, H., Mendiola, E. A., Neelakantan, S. et al. (2022). A machine learning model to estimate myocardial stiffness from EDPVR. Sci Rep 12, 5433. https://doi.org/10.1038/s41598-022-09128-6.

Lokugamage, N., Chowdhury, I. H., Biediger, R. J. et al. (2021). Use of a small molecule integrin activator as a systemically administered vaccine adjuvant in controlling Chagas disease. NPJ Vaccines 6, 114. https://doi.org/10.1038/s41541-021-00378-5.

Bakthavatsalam, D., Craft, J. W., Kazansky, A. et al. (2020). Identification of Inhibitors of Integrin Cytoplasmic Domain Interactions With Syk. Front Immunol 11, 575085. https://doi.org/10.3389/fimmu.2020.575085.

Avazmohammadi, R., Mendiola, E., Li, D. et al. (2019). Interactions between structural remodeling and volumetric growth in right ventricle in response to pulmonary arterial hypertension. J Biomech Eng. https://doi.org/10.1115/1.4044174.

Avazmohammadi, R., Mendiola, E. A., Soares, J. S. et al. (2019). A computational cardiac model for the adaptation to pulmonary arterial hypertension in the rat. Ann Biomed Eng 47, 138–153. https://doi.org/10.1007/s10439-018-02130-y.

Woodside, D. G., Tanifum, E. A., Ghaghada, K. B. et al. (2018). Magnetic resonance imaging of atherosclerotic plaque at clinically relevant field strengths (1T) by targeting the integrin α4β1. Sci Rep 8, 3733. https://doi.org/10.1038/s41598-018-21893-x.

Kumar, V. A., Liu, Q., Wickremasinghe, N. C. et al. (2016). Treatment of hind limb ischemia using angiogenic peptide nanofibers. Biomaterials 98, 113–119. https://doi.org/10.1016/j.biomaterials.2016.04.032.

Texas Heart Institute Positions

Interests

Education

Undergraduate:

Postgraduate:

Fellowships:

Honors, Awards and Memberships

Publications

Recent News

7 Hills Pharma Announces First Patient in Phase 1b/2a Clinical Trial Testing Alintegimod Against aPD-1-resistant Solid Tumors

A Discovery by The Texas Heart Institute & 7 Hills Pharma Continues Development under a $4.7 Million CPRIT Grant to Address Cancer Treatment Disparities

Scientists have found a beautiful way to amplify vaccines